Merus Labs International Inc. Form 6-K December 19, 2014

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of **December 2014** 

Commission File No. 00-30082

## MERUS LABS INTERNATIONAL INC.

(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F [X] Form 40-F []
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(1)$ [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(7)$ [ ]

## Edgar Filing: Merus Labs International Inc. - Form 6-K

## **SUBMITTED HEREWITH**

Exhibits	
<u>99.1</u>	Annual Report 2014 For the Years Ended September 30, 2014 and 2013
99.2	Certification of Interim Filings - CEO
99.3	Certification of Interim Filings - CFO

## Edgar Filing: Merus Labs International Inc. - Form 6-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 19, 2014

#### MERUS LABS INTERNATIONAL INC.

Andrew Patient
Andrew Patient
Chief Financial Officer